NO20020569L - Substituerte pyridaziner og kondenserte pyridaziner med angiogeneseinhiberende aktivitet - Google Patents

Substituerte pyridaziner og kondenserte pyridaziner med angiogeneseinhiberende aktivitet

Info

Publication number
NO20020569L
NO20020569L NO20020569A NO20020569A NO20020569L NO 20020569 L NO20020569 L NO 20020569L NO 20020569 A NO20020569 A NO 20020569A NO 20020569 A NO20020569 A NO 20020569A NO 20020569 L NO20020569 L NO 20020569L
Authority
NO
Norway
Prior art keywords
pyridazines
inhibitory activity
condensed
substituted
angiogenesis inhibitory
Prior art date
Application number
NO20020569A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020569D0 (no
Inventor
Jacques Dumas
Holia N Hatoum-Mokdad
Teddy Kite Joe
Harold C E Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Ning Su
Stephen James Boyer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20020569D0 publication Critical patent/NO20020569D0/no
Publication of NO20020569L publication Critical patent/NO20020569L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20020569A 1999-08-10 2002-02-05 Substituerte pyridaziner og kondenserte pyridaziner med angiogeneseinhiberende aktivitet NO20020569L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10
PCT/US2000/021579 WO2001010859A1 (en) 1999-08-10 2000-08-08 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Publications (2)

Publication Number Publication Date
NO20020569D0 NO20020569D0 (no) 2002-02-05
NO20020569L true NO20020569L (no) 2002-04-10

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020569A NO20020569L (no) 1999-08-10 2002-02-05 Substituerte pyridaziner og kondenserte pyridaziner med angiogeneseinhiberende aktivitet

Country Status (19)

Country Link
EP (1) EP1208096B1 (enExample)
JP (1) JP2003506447A (enExample)
KR (1) KR20020019969A (enExample)
CN (1) CN1378543A (enExample)
AR (1) AR025068A1 (enExample)
AT (1) ATE265448T1 (enExample)
AU (1) AU775237B2 (enExample)
BR (1) BR0013113A (enExample)
CA (1) CA2381621A1 (enExample)
CO (1) CO5180637A1 (enExample)
DE (1) DE60010280T2 (enExample)
ES (1) ES2219382T3 (enExample)
IL (1) IL147885A0 (enExample)
MX (1) MXPA02001324A (enExample)
NO (1) NO20020569L (enExample)
NZ (1) NZ517087A (enExample)
PE (1) PE20010494A1 (enExample)
WO (1) WO2001010859A1 (enExample)
ZA (1) ZA200200691B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GT200000158A (es) * 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CA2499738A1 (en) * 2002-09-24 2004-04-08 Novartis Ag Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
EP1562591A1 (en) * 2002-11-12 2005-08-17 Novartis AG Treatment of mesothelioma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2137177B1 (en) 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
US8962027B2 (en) 2007-06-19 2015-02-24 Rynel Inc. Materials comprising water-soluble polymer particles and methods of making and using them
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
AU2009279760B2 (en) * 2008-08-04 2012-07-12 Amgen Inc. Aurora kinase modulators and methods of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
WO1996005176A1 (en) * 1994-08-09 1996-02-22 Eisai Co., Ltd. Fused pyridazine compound
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2366857C (en) * 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases

Also Published As

Publication number Publication date
CA2381621A1 (en) 2001-02-15
AU775237B2 (en) 2004-07-22
NZ517087A (en) 2004-05-28
IL147885A0 (en) 2002-08-14
JP2003506447A (ja) 2003-02-18
NO20020569D0 (no) 2002-02-05
DE60010280T2 (de) 2009-10-15
KR20020019969A (ko) 2002-03-13
EP1208096B1 (en) 2004-04-28
AR025068A1 (es) 2002-11-06
ES2219382T3 (es) 2004-12-01
PE20010494A1 (es) 2001-06-27
CO5180637A1 (es) 2002-07-30
MXPA02001324A (es) 2002-07-22
ATE265448T1 (de) 2004-05-15
CN1378543A (zh) 2002-11-06
WO2001010859A1 (en) 2001-02-15
EP1208096A1 (en) 2002-05-29
ZA200200691B (en) 2003-10-29
DE60010280D1 (de) 2004-06-03
BR0013113A (pt) 2002-04-30
AU6895400A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
NO20021520D0 (no) Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet
DK0970070T3 (da) Phthalaziner med angiogenesis-hæmmende aktivitet
EP1240160A4 (en) SUBSTITUTED PYRIDAZINE WITH CYTOKIN INHIBITING ACTIVITY
NO20020569L (no) Substituerte pyridaziner og kondenserte pyridaziner med angiogeneseinhiberende aktivitet
NO20021449L (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og deres anvendelse
NO991951D0 (no) Tienopyrimidiner med fosfodiesterase V-inhiberende virkning
NO973143L (no) Heterocyklisk kondenserte pyridiner
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
NO20030625D0 (no) Kinolinderivater med VEGF-inhiberende aktivitet
DE60017338D1 (de) Führungsdraht
NO20024201D0 (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
DK1164996T3 (da) Transdermalt terapeutisk system med nikotin og tilsat monoterpenketoner
FI20001593A7 (fi) Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
NO20013409D0 (no) Anvendelse av pyrimidin-derivater for forhindring og behandling av cerebral ischemi
NO20021305D0 (no) DNA-konstruksjon og dens anvendelse
PT1272456E (pt) Inibidores de angiogenese de hidrazida e alcoxiamida
ZA200500863B (en) Condensed pyridines and pyrimidines with Tie2 (tek) activity.
NO20023003D0 (no) Benzofenon-glykopyranosider, samt fremstilling og terapeutisk anvendelse
DK1177196T3 (da) Heteroaryldiazabicycloalkaner, deres fremstilling og anvendelse
ES1044792Y (es) Colchon perfeccionado.
ITMI990674V0 (it) Indumento per disabili e/o invalidi
ITUD990080A0 (it) Moka autoservente
DK1127274T3 (da) Detektor og deres anvendelse
NO995922D0 (no) Kjelke

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application